Changes in arginine are inversely associated with type 2 diabetes: A case-cohort study in the PREDIMED trial.


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
02 2019
Historique:
received: 15 05 2018
revised: 16 08 2018
accepted: 23 08 2018
pubmed: 28 8 2018
medline: 10 9 2019
entrez: 28 8 2018
Statut: ppublish

Résumé

The associations between arginine-based metabolites and incident type 2 diabetes (T2D) are unknown. We employed a case-cohort design, nested within the PREDIMED trial, to examine six plasma metabolites (arginine, citrulline, ornithine, asymmetric dimethylarginine [ADMA], symmetric dimethylarginine [SDMA] and N-monomethyl-l-arginine [NMMA]) among 892 individuals (251 cases) for associations with incident T2D and insulin resistance. Weighted Cox models with robust variance were used. The 1-year changes in arginine (adjusted hazard ratio [HR] per SD 0.68, 95% confidence interval [CI] 0.49, 0.95; Q4 vs. Q1 0.46, 95% CI 0.21, 1.04; P trend = 0.02) and arginine/ADMA ratio (adjusted HR per SD 0.73, 95% CI 0.51, 1.04; Q4 vs. Q1 0.52, 95% CI 0.22, 1.25; P trend = 0.04) were associated with a lower risk of T2D. Positive changes of citrulline and ornithine, and negative changes in SDMA and arginine/(ornithine + citrulline) were associated with concurrent 1-year changes in homeostatic model assessment of insulin resistance. Individuals in the low-fat-diet group had a higher risk of T2D for 1-year changes in NMMA than individuals in Mediterranean-diet groups (P interaction = 0.02). We conclude that arginine bioavailability is important in T2D pathophysiology.

Identifiants

pubmed: 30146690
doi: 10.1111/dom.13514
pmc: PMC6329637
mid: NIHMS986825
doi:

Substances chimiques

omega-N-Methylarginine 27JT06E6GR
Citrulline 29VT07BGDA
symmetric dimethylarginine 49787G1ULV
N,N-dimethylarginine 63CV1GEK3Y
Arginine 94ZLA3W45F
Ornithine E524N2IXA3

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-401

Subventions

Organisme : NIDDK NIH HHS
ID : F31 DK114938
Pays : United States
Organisme : NIDDK NIH HHS
ID : K99 DK119412
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK102896
Pays : United States

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Références

PLoS One. 2016 Nov 3;11(11):e0165811
pubmed: 27812151
Diabetes Obes Metab. 2012 Oct;14(10):893-900
pubmed: 22553931
J Clin Epidemiol. 1999 Dec;52(12):1165-72
pubmed: 10580779
Ann Intern Med. 2014 Jan 7;160(1):1-10
pubmed: 24573661
Diabetes Obes Metab. 2000 Oct;2(5):285-92
pubmed: 11225743
Nephrol Dial Transplant. 2006 Sep;21(9):2446-51
pubmed: 16766542
Diabetologia. 2010 Oct;53(10):2093-104
pubmed: 20496053
Diabetes Obes Metab. 2007 Jul;9(4):455-63
pubmed: 17587387
Diabetes Care. 2003 Jan;26(1):168-71
pubmed: 12502675
J Am Coll Cardiol. 2009 Jun 2;53(22):2061-7
pubmed: 19477356
PLoS One. 2013 Jun 24;8(6):e66823
pubmed: 23826148
J Clin Invest. 2017 Dec 1;127(12):4394-4402
pubmed: 29083323
Diabetes Care. 2001 May;24(5):875-80
pubmed: 11347747
N Engl J Med. 1993 Dec 30;329(27):2002-12
pubmed: 7504210
Diabetes Obes Metab. 2018 Jun;20(6):1350-1360
pubmed: 29419909
Sci Rep. 2015 Jul 09;5:11918
pubmed: 26156880
J Am Diet Assoc. 2008 Jul;108(7):1134-44; discussion 1145
pubmed: 18589019
Curr Protein Pept Sci. 2017;18(6):599-608
pubmed: 27356939
Rev Diabet Stud. 2010 Spring;7(1):15-25
pubmed: 20703435
Diabetes Obes Metab. 2010 Oct;12 Suppl 2:126-33
pubmed: 21029309

Auteurs

Edward Yu (E)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Miguel Ruiz-Canela (M)

Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
Medicina Preventiva y Salud Pública, IdiSNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Cristina Razquin (C)

Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.

Marta Guasch-Ferré (M)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain.

Estefania Toledo (E)

Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
Medicina Preventiva y Salud Pública, IdiSNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Dong D Wang (DD)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Christopher Papandreou (C)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain.

Courtney Dennis (C)

Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.

Clary Clish (C)

Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.

Liming Liang (L)

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Monica Bullo (M)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain.

Dolores Corella (D)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Preventive Medicine, University of Valencia, Valencia, Spain.

Montserrat Fitó (M)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Preventive Medicine, University of Valencia, Valencia, Spain.

Mario Gutiérrez-Bedmar (M)

Department of Preventive Medicine, University of Málaga, Málaga, Spain.

José Lapetra (J)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Family Medicine, Unit Research, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain.

Ramón Estruch (R)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Internal Medicine, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDI- BAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.

Emilio Ros (E)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Lipid Clinic, Department of Endocrinology and Nutrition, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Montserrat Cofán (M)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Lipid Clinic, Department of Endocrinology and Nutrition, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Fernando Arós (F)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Cardiology, University Hospital of Álava, Vitoria, Spain.

Dora Romaguera (D)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Epidemiología Clínica y Salud Pública, Health Research Institute of Palma (IdISPa), University Hospital Son Espases, Palma de Mallorca, Spain.

Lluis Serra-Majem (L)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Clinical Sciences, Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain.

Jose V Sorlí (JV)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Preventive Medicine, University of Valencia, Valencia, Spain.

Jordi Salas-Salvadó (J)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain.

Frank B Hu (FB)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Massachusetts.

Miguel A Martínez-González (MA)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
Medicina Preventiva y Salud Pública, IdiSNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH